A Comprehensive Monograph on Lisdexamfetamine (DB01255): Pharmacology, Clinical Utility, and Safety

Executive Summary

Lisdexamfetamine is a long-acting central nervous system (CNS) stimulant belonging to the amphetamine class of drugs.[1] It is uniquely formulated as a pharmacologically inactive prodrug, in which the active substance, dextroamphetamine, is covalently bonded to the amino acid L-lysine.[3] This chemical design governs its distinct pharmacokinetic profile, characterized by a gradual enzymatic conversion to dextroamphetamine within the bloodstream, leading to a smooth onset of action and a prolonged therapeutic effect of up to 14 hours.[3] This rate-limited activation may also contribute to a potentially lower abuse liability compared to immediate-release amphetamine formulations.[6]

The United States Food and Drug Administration (FDA) has approved lisdexamfetamine for two primary indications: the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients aged six years and older and in adults, and the treatment of moderate-to-severe Binge Eating Disorder (BED) in adults.[8] Its efficacy in these conditions is attributed to the ability of its active metabolite, dextroamphetamine, to increase the synaptic availability of dopamine and norepinephrine, key neurotransmitters involved in regulating attention, executive function, and impulse control.[3]

Despite its sophisticated prodrug design, lisdexamfetamine is classified as a Schedule II controlled substance in the United States due to the high potential for abuse and dependence associated with its active amphetamine metabolite.[3] This status is underscored by a prominent black box warning on its label, mandating careful patient screening for risk of substance abuse and continuous monitoring throughout treatment.[8] This report provides a comprehensive examination of lisdexamfetamine, covering its chemical properties, pharmacology, clinical applications, safety profile, and regulatory context.

Identification and Physicochemical Properties

Precise identification of a pharmaceutical agent is fundamental for research, clinical practice, and regulatory oversight. Lisdexamfetamine is identified by a specific set of chemical names, codes, and structural characteristics that distinguish it from other compounds. It is most commonly available for clinical use as a dimesylate salt.

Nomenclature and Identification Codes

The compound is known by several names and is cataloged in major chemical and drug databases under unique identifiers.[3]

• International Nonproprietary Name (INN): Lisdexamfetamine
• Synonyms: Lisdexamphetamine, L-lysine-D-amphetamine, L-lysine-dextroamphetamine [1]
• IUPAC Name: (2S)-2,6-Diamino-N-hexanamide [3]
• DrugBank Accession Number: DB01255 [3]
• CAS Number: 608137-32-2 (for the free base).[3] Alternate CAS numbers exist for its salt forms, including 608137-33-3 for lisdexamfetamine dimesylate and 914480-48-1 for the dihydrochloride salt.[13]

Chemical Structure and Stereochemistry

Lisdexamfetamine is a small molecule formed by the condensation of two distinct chiral molecules: the essential amino acid L-lysine and the potent CNS stimulant dextroamphetamine.[3] The stereochemistry is critical to its identity and function.

• Chemical Formula: C15​H25​N3​O [6]
• Molecular Weight (Free Base):
• Average: 263.3785 g/mol [10]
• Monoisotopic: 263.199762437 g/mol [10]
• Molecular Weight (Dimesylate Salt): 455.59 g/mol [6]
• Structural Identifiers:
• InChI: InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1 [3]
• InChIKey: VOBHXZCDAVEXEY-JSGCOSHPSA-N [3]
• SMILES: CC@HCC1=CC=CC=C1

Physical and Chemical Properties

The dimesylate salt of lisdexamfetamine, the form used in pharmaceutical preparations, is a white to off-white powder. While comprehensive experimental data is limited, certain physicochemical properties have been predicted through computational models.

• Predicted Boiling Point: 488.0±45.0 °C
• Predicted Density: 1.045±0.06 g/cm3
• Predicted pKa: 15.11±0.46

Table 1: Physicochemical and Identification Data for Lisdexamfetamine

Pharmacology and Mechanism of Action

Lisdexamfetamine's clinical effects are a direct consequence of its unique prodrug design and the well-established neuropharmacology of its active metabolite, dextroamphetamine.

Drug Classification and Therapeutic Category

Lisdexamfetamine is classified as a CNS stimulant and belongs to the phenethylamine and amphetamine chemical classes. Within the Anatomical Therapeutic Chemical (ATC) classification system, it is categorized as N06BA12, a centrally acting sympathomimetic agent used for ADHD.

The Prodrug Mechanism: Enzymatic Conversion to Dextroamphetamine

The defining feature of lisdexamfetamine is its identity as a chemically formulated prodrug, a concept first proposed in 1958 to describe pharmacologically inactive compounds that are metabolized in the body to an active drug. Lisdexamfetamine itself is inert; the L-lysine moiety renders the molecule incapable of binding to the monoamine transporters that are the targets of amphetamine.

Following oral administration and absorption into the bloodstream, lisdexamfetamine undergoes rate-limited enzymatic hydrolysis, a process primarily carried out by enzymes in red blood cells. This reaction cleaves the amide bond, releasing the two constituent components: dextroamphetamine, the pharmacologically active agent, and L-lysine, a naturally occurring essential amino acid. This biological activation pathway is distinct from mechanically engineered extended-release formulations (e.g., those using beaded technology or osmotic pumps) and is not substantially influenced by conditions in the gastrointestinal tract, such as pH or transit time.

This prodrug design has profound clinical implications. The rate-limited conversion process creates a gradual rise in plasma dextroamphetamine levels, leading to a smoother onset and a more consistent, prolonged therapeutic effect compared to immediate-release stimulants. Furthermore, because the drug requires enzymatic conversion in the blood to become active, routes of administration commonly used for abuse, such as insufflation (snorting) or intravenous injection, do not bypass this metabolic step or produce a more rapid "rush". This is the scientific basis for its potentially lower abuse liability relative to other amphetamine preparations. Despite this "safer" design, the fact that its active metabolite is the highly abusable dextroamphetamine led regulators to place it in the most restrictive category for legally marketed drugs, Schedule II, even before its initial FDA approval, demonstrating that the ultimate pharmacological activity of the final metabolite is the primary consideration for scheduling.

Molecular Targets and Neurotransmitter Modulation

All therapeutic activity of lisdexamfetamine is attributable to its active metabolite, dextroamphetamine. The primary mechanism of action involves the potentiation of dopaminergic and noradrenergic neurotransmission in the brain. Dextroamphetamine achieves this through several actions:

1. Reuptake Inhibition: It acts as a competitive inhibitor of the dopamine transporter (DAT) and the norepinephrine transporter (NET), blocking the reuptake of these neurotransmitters from the synaptic cleft back into the presynaptic neuron.
2. Enhanced Release: It promotes the efflux (release) of dopamine and norepinephrine from the presynaptic neuron into the extraneuronal space.
3. Vesicular Transport Inhibition: It is an inhibitor of the vesicular monoamine transporter 2 (VMAT2), which is responsible for packaging monoamines into synaptic vesicles for later release.
4. Receptor Agonism: It functions as an agonist at the Trace Amine-Associated Receptor 1 (TAAR1), a receptor that modulates monoamine transporter function.

Dextroamphetamine also has a much weaker affinity for the serotonin transporter (SERT) and exhibits weak monoamine oxidase (MAO) inhibitory properties.

Pharmacodynamic Effects on Executive Function and Impulse Control

The enhanced dopaminergic and noradrenergic activity in key brain circuits, particularly the mesocorticolimbic projection and the prefrontal cortex, is believed to underlie lisdexamfetamine's therapeutic efficacy. These pathways are critical for regulating executive functions, including attention, planning, working memory, and behavioral inhibition.

The efficacy of lisdexamfetamine in treating both ADHD and BED highlights a shared neurobiological substrate related to impulse control. In ADHD, which is characterized by functional impairments in these neurotransmitter systems, the drug's action helps to improve focus, reduce hyperactivity, and decrease impulsivity. Similarly, in BED, the enhanced neurotransmission in the prefrontal cortex strengthens cognitive control over behavior. This may help patients reduce impulsive decisions and override the prepotent, compulsive urges to engage in binge eating episodes. The drug's success in these two seemingly different disorders provides strong evidence for a unifying model where a deficit in the brain's executive control "braking system" is a common pathophysiological factor.

Pharmacokinetics and Pharmacodynamics

The pharmacokinetic profile of lisdexamfetamine is defined by its conversion from an inactive prodrug to an active metabolite, which dictates its absorption, distribution, metabolism, excretion (ADME), half-life, and duration of effect.

Absorption, Distribution, Metabolism, and Excretion (ADME)

• Absorption: After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract. In a fasted state, the time to reach maximum plasma concentration (Tmax​) for the prodrug is approximately 1 hour, while the active metabolite, dextroamphetamine, reaches its Tmax​ in about 3.5 hours. The presence of food can delay the Tmax​ for both compounds by about 1 hour but does not significantly alter the overall exposure (AUC) to dextroamphetamine.
• Distribution: The active metabolite, dextroamphetamine, is known to readily cross the blood-brain barrier to exert its effects on the CNS.
• Metabolism: Lisdexamfetamine's metabolism is its most distinctive pharmacokinetic feature. It is not metabolized by the cytochrome P450 (CYP) enzyme system in the liver, a fact that minimizes its potential for many common drug-drug interactions. Instead, it is hydrolyzed in the blood by enzymes in red blood cells to dextroamphetamine and L-lysine. Dextroamphetamine itself can be further metabolized, including to inactive metabolites like hippuric acid.
• Excretion: The drug and its metabolites are eliminated primarily via the kidneys. Following administration of a radiolabeled dose, approximately 96% of the radioactivity was recovered in the urine over 120 hours. This urinary output consisted of approximately 42% related to amphetamine, 25% hippuric acid, and only 2% intact lisdexamfetamine, confirming that the conversion to the active drug is nearly complete in the body.

Half-Life and Duration of Therapeutic Effect

The clinically relevant half-life is that of the active metabolite, not the transient prodrug.

• Lisdexamfetamine (Prodrug): The plasma elimination half-life is very short, averaging less than one hour. Its concentrations are typically low and become undetectable within 8 hours of administration.
• Dextroamphetamine (Active Metabolite): The plasma elimination half-life is approximately 10 to 12 hours in healthy adults. In pediatric patients (ages 6-12), the half-life is slightly shorter, ranging from 8.6 to 9.5 hours.
• Duration of Action: The therapeutic effects of a single dose are long-lasting. Clinical studies have shown that lisdexamfetamine begins to work within 1.5 to 2 hours and provides consistent symptom control for up to 14 hours after administration.

Table 2: Summary of Key Pharmacokinetic Parameters

Clinical Applications and Efficacy

Lisdexamfetamine has demonstrated efficacy in two FDA-approved indications and is being investigated for several off-label uses.

A. FDA-Approved Indication: Attention-Deficit/Hyperactivity Disorder (ADHD)

Lisdexamfetamine is approved for the treatment of ADHD in adults and children aged six years and older. The rationale for its use stems from the neurobiological model of ADHD, which posits that the disorder is associated with functional deficits in dopaminergic and noradrenergic pathways responsible for executive function. Stimulant medications are a first-line treatment for ADHD, with approximately 80% of individuals who use them experiencing an improvement in symptoms.

Multiple clinical trials have established the efficacy of lisdexamfetamine in this population. Long-term continuous stimulant therapy is effective in reducing the core symptoms of ADHD—inattention, hyperactivity, and impulsivity—while also enhancing quality of life, academic achievement, and a wide range of functional outcomes. Clinical studies have shown that in adults, lisdexamfetamine improves attention as early as 2 hours post-dose and for as long as 14 hours. In children, the onset of action is observed within 1.5 hours, with effects lasting up to 13 hours.

B. FDA-Approved Indication: Moderate-to-Severe Binge Eating Disorder (BED)

Lisdexamfetamine is also approved for the treatment of moderate-to-severe BED in adults. This approval, granted on January 30, 2015, was a landmark event, as lisdexamfetamine became the first medication ever approved by the FDA for this condition. The FDA granted it a priority review, a designation reserved for drugs that may provide a significant improvement in the treatment of a serious condition. This regulatory action served to medically validate BED as a treatable neurobiological disorder, shifting its perception from a behavioral issue to a condition with a specific pharmacological target.

The therapeutic mechanism is thought to be the same as in ADHD: enhancing cognitive control and reducing the impulsivity that drives binge eating episodes. The approval was based on two pivotal clinical trials involving 724 adults with moderate-to-severe BED. The results demonstrated that participants taking lisdexamfetamine experienced a statistically significant decrease in the number of binge-eating days per week and showed reductions in obsessive-compulsive behaviors related to bingeing compared to those taking a placebo. For some patients, it may take up to 12 weeks of treatment to observe a significant reduction in binge days.

It is critical to note that the FDA label includes a limitation of use, explicitly stating that lisdexamfetamine is not indicated or recommended for weight loss or the treatment of obesity. The use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.

C. Investigational and Off-Label Uses

Beyond its approved indications, lisdexamfetamine has been studied for other conditions, reflecting the broad utility of CNS stimulants.

• Treatment-Resistant Depression: Completed Phase 2 clinical trials have explored lisdexamfetamine as an adjunctive therapy for adults with Major Depressive Disorder (MDD) who have had an inadequate response to standard antidepressant treatment. These studies have particularly focused on patients with persistent impairments in executive function, a common residual symptom of depression.
• Narcolepsy and Chronic Fatigue Syndrome (CFS): Like other amphetamines, lisdexamfetamine is used off-label to manage the excessive daytime sleepiness characteristic of narcolepsy. Additionally, a completed Phase 4 clinical trial has formally investigated its efficacy and safety for treating adults with CFS.
• Substance Use Disorders: The potential role of lisdexamfetamine in treating other impulse-control disorders has been explored. A completed Phase 1/2 open-label pilot study investigated its utility for cocaine dependence. Other early-phase trials have evaluated its abuse potential in individuals with a history of stimulant abuse to better characterize its risk profile.

Dosage, Formulations, and Administration

Proper dosing and administration are crucial for maximizing efficacy and minimizing adverse effects. Lisdexamfetamine is available in multiple formulations and strengths to allow for individualized treatment.

Available Formulations and Strengths

Lisdexamfetamine is marketed in two oral formulations :

• Capsules: Available in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. Each strength has a unique color combination and imprint for easy identification (e.g., 30 mg capsule is white body/orange cap imprinted with S489 and 30 mg).
• Chewable Tablets: Available in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. The tablets are debossed with the strength and are shape-coded for identification (e.g., 10 mg is round, 30 mg is arc triangular).

The capsules and chewable tablets are considered bioequivalent and can be substituted on a milligram-for-milligram basis.

Recommended Dosing and Titration Schedules

The dosing strategy involves starting low and titrating upward to the lowest effective dose. The schedules for the two approved indications are as follows :

Table 3: Dosing Regimens for Approved Indications

Administration Guidelines

To ensure proper absorption and minimize side effects like insomnia, the following administration guidelines should be followed :

• Take once daily in the morning, with or without food. Afternoon doses should be avoided.
• Capsules should be swallowed whole. Alternatively, the capsule can be opened, and the entire contents can be sprinkled into yogurt, water, or orange juice. The mixture should be stirred until dispersed and consumed immediately.
• Chewable tablets must be chewed thoroughly before being swallowed.
• A single dose should not be divided. Patients should take the entire contents of one capsule or one chewable tablet per day.

Dosage Adjustments in Special Populations

Dose adjustments are necessary for patients with impaired kidney function :

• Severe Renal Impairment (Glomerular filtration rate 15 to <30 mL/min/1.73 m2): The maximum recommended dose is 50 mg per day.
• End-Stage Renal Disease (ESRD) (GFR <15 mL/min/1.73 m2): The maximum recommended dose is 30 mg per day.
• Lisdexamfetamine and its active metabolite dextroamphetamine are not dialyzable, meaning hemodialysis is not an effective method for removing the drug in cases of overdose.

Safety and Tolerability Profile

The safety profile of lisdexamfetamine is consistent with that of other amphetamine-based CNS stimulants and is dominated by risks related to cardiovascular effects, psychiatric symptoms, and a high potential for abuse and dependence.

A. Black Box Warning: Potential for Abuse and Dependence

Lisdexamfetamine carries a black box warning, the most serious warning issued by the FDA, highlighting its high potential for abuse and dependence. CNS stimulants, including amphetamines, can lead to severe psychological or physical dependence. This necessitates a thorough clinical assessment of abuse risk before initiating therapy and continuous monitoring for signs of misuse, abuse, or diversion throughout the treatment course. Patients should be educated about the risks and the importance of storing the medication securely.

B. Contraindications

Lisdexamfetamine should not be used in patients with :

• A history of hypersensitivity to amphetamine products or any other ingredients in the formulation. Anaphylactic reactions, angioedema, and Stevens-Johnson Syndrome have been reported.
• Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of discontinuing an MAOI, due to the risk of a life-threatening hypertensive crisis.

C. Warnings and Precautions

• Serious Cardiovascular Reactions: Sudden death, stroke, and myocardial infarction have been reported in adults taking CNS stimulants at recommended doses. Sudden death has also been reported in children and adolescents with pre-existing structural cardiac abnormalities or other serious heart problems. A careful pre-treatment screening, including personal and family cardiac history and a physical exam, is mandatory. The drug should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, or serious heart arrhythmias.
• Blood Pressure and Heart Rate Increases: Lisdexamfetamine can cause modest but clinically relevant increases in blood pressure (mean 2-4 mmHg) and heart rate (mean 3-6 bpm). Blood pressure and pulse should be monitored regularly.
• Adverse Psychiatric Reactions: Stimulants may cause or exacerbate psychiatric symptoms. This includes worsening of pre-existing psychosis, induction of manic episodes in patients with bipolar disorder, and the emergence of new psychotic or manic symptoms (e.g., hallucinations, delusional thinking) in individuals with no prior history. Screening for bipolar disorder prior to treatment is recommended.
• Suppression of Growth: In pediatric patients, long-term use of stimulants has been associated with appetite suppression, weight loss, and a slowing of the growth rate. Height and weight should be monitored closely during treatment.
• Peripheral Vasculopathy, including Raynaud's Phenomenon: Stimulants can cause peripheral vasoconstriction, leading to symptoms like numbness, pain, or discoloration in the fingers and toes. While usually mild, rare cases of digital ulceration have occurred.
• Serotonin Syndrome: This potentially life-threatening condition can occur when amphetamines are co-administered with other serotonergic drugs (see Drug Interactions). Symptoms include mental status changes, autonomic instability, and neuromuscular hyperactivity. If it occurs, treatment should be discontinued immediately.

D. Common and Serious Adverse Reactions

The most frequently reported adverse effects are consistent with the stimulant properties of the drug.

• Common Side Effects: In both ADHD and BED populations, common reactions (incidence ≥5% and at least twice the rate of placebo) include decreased appetite (anorexia), insomnia, dry mouth, anxiety, irritability, weight loss, diarrhea, nausea, and upper abdominal pain. In BED patients, increased heart rate, constipation, and feeling jittery are also common.
• Overdose: Manifestations of an overdose can be severe and include restlessness, tremor, hyperreflexia, rapid respiration, confusion, hallucinations, panic states, hyperpyrexia, and rhabdomyolysis. Cardiovascular effects like arrhythmias and circulatory collapse can occur. Fatal poisoning is often preceded by convulsions and coma.

E. Drug-Drug Interactions

There are over 396 drugs known to interact with lisdexamfetamine, with over 100 of these interactions classified as major. A crucial aspect of these interactions is that many are driven by the pharmacology of the active metabolite, dextroamphetamine, rather than the parent prodrug. While lisdexamfetamine's conversion is independent of the CYP450 system, dextroamphetamine itself is a substrate for enzymes like CYP2D6. This explains why a CYP2D6 inhibitor (e.g., bupropion, fluoxetine) can increase dextroamphetamine exposure and heighten the risk of adverse events, even though it does not affect the prodrug's activation.

Table 4: Clinically Significant Drug Interactions

Interacting Drug/Class	Mechanism/Effect	Clinical Recommendation
Monoamine Oxidase Inhibitors (MAOIs) (e.g., phenelzine, selegiline)	MAOIs slow amphetamine metabolism and increase the release of norepinephrine, leading to a synergistic effect that can cause a severe hypertensive crisis.	Contraindicated. Do not use within 14 days of MAOI administration.
Serotonergic Drugs (e.g., SSRIs, SNRIs, triptans, fentanyl, tramadol)	Co-administration increases synaptic serotonin levels from multiple mechanisms, raising the risk of potentially life-threatening serotonin syndrome.	Use with caution/Monitor closely. Initiate with lower doses and monitor for symptoms of serotonin syndrome (e.g., confusion, agitation, tachycardia). Discontinue immediately if syndrome occurs.
Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, imipramine)	TCAs can potentiate the cardiovascular effects of amphetamine, possibly by increasing its concentration in the brain.	Avoid or Use Alternate Drug. Monitor blood pressure and heart rate frequently. Dosage adjustment or alternative therapy may be required.
Urinary Alkalinizing Agents (e.g., sodium bicarbonate, acetazolamide)	These agents increase urine pH, which decreases the renal excretion of amphetamine, leading to higher blood levels and a prolonged effect.	Use with caution/Monitor. Dosage adjustment may be necessary.
Urinary Acidifying Agents (e.g., ascorbic acid [Vitamin C])	These agents decrease urine pH, which increases the renal excretion of amphetamine, leading to lower blood levels and potentially reduced efficacy.	Monitor for efficacy. Dosage adjustment may be necessary.
CYP2D6 Inhibitors (e.g., bupropion, fluoxetine, paroxetine)	These drugs inhibit the metabolism of dextroamphetamine (the active metabolite), which can increase its plasma concentration and elevate the risk of adverse effects, including serotonin syndrome.	Use with caution/Monitor closely. A lower starting dose of lisdexamfetamine may be warranted. Monitor for increased side effects.
Antihypertensive Agents	Lisdexamfetamine is a sympathomimetic and can increase blood pressure, thereby antagonizing the effects of antihypertensive medications.	Monitor blood pressure. Adjustments to the antihypertensive regimen may be needed.
Antipsychotics	Dopamine antagonists (antipsychotics) may block the central stimulant effects of amphetamines.	Monitor for efficacy. The therapeutic effect of lisdexamfetamine may be diminished.

Comparative Analysis with Other CNS Stimulants

Selecting a stimulant for ADHD often involves choosing between amphetamine-based products, like lisdexamfetamine and Adderall, and methylphenidate-based products, like Ritalin. The choice depends on individual patient factors, including desired duration of action, side effect tolerance, and history of response.

Lisdexamfetamine vs. Adderall (Mixed Amphetamine Salts)

• Composition: Lisdexamfetamine is a prodrug of a single isomer, dextroamphetamine. Adderall is a combination of four different amphetamine salts, resulting in a 3:1 ratio of dextroamphetamine to the less potent levoamphetamine.
• Pharmacokinetics and Duration: The key difference lies in the delivery system. Lisdexamfetamine's prodrug conversion results in a slower, more gradual onset (60-90 minutes) and a longer, smoother duration of effect (up to 14 hours). Immediate-release (IR) Adderall acts faster (within 30-45 minutes) but lasts only 4-6 hours, often requiring multiple daily doses. Extended-release (XR) Adderall lasts approximately 12 hours.
• Side Effects and Abuse Potential: Both have similar side effect profiles. However, the smoother pharmacokinetic curve of lisdexamfetamine may result in less intense side effects, such as fewer "jitters" or end-of-dose "crashes". Due to its rate-limited conversion, lisdexamfetamine is generally considered to have a lower potential for abuse via non-oral routes than Adderall IR.

Lisdexamfetamine vs. Ritalin (Methylphenidate)

• Chemical Class: Lisdexamfetamine is an amphetamine, while Ritalin is methylphenidate. Although both increase dopamine and norepinephrine levels, their precise interactions with monoamine transporters differ.
• Pharmacokinetics and Duration: Ritalin IR has a very rapid onset (20-30 minutes) but a short duration of action (3-4 hours), making it suitable for short-term symptom control or for patients who need flexibility in dosing. Lisdexamfetamine's single daily dose provides all-day coverage, which can be an advantage for adherence.
• Efficacy and Patient Preference: Both are considered highly effective first-line treatments. Some evidence suggests that methylphenidate may be preferred for children and adolescents, while amphetamines are often preferred for adults, though individual response is the ultimate guide.
• Side Effects: While profiles overlap, some studies suggest Ritalin may be associated with less appetite suppression and anxiety compared to amphetamines, but this varies significantly among individuals.

Table 5: Comparative Profile: Lisdexamfetamine vs. Adderall vs. Ritalin

Regulatory Status and Commercial Information

Lisdexamfetamine is a globally recognized medication, but its distribution is tightly controlled due to its stimulant nature.

Controlled Substance Scheduling

The high potential for abuse of its active metabolite, dextroamphetamine, has led to strict regulatory controls worldwide.

• United States: Lisdexamfetamine is a Schedule II controlled substance under the federal Controlled Substances Act. The Drug Enforcement Administration (DEA) finalized this placement in May 2007, effective upon its FDA approval, imposing stringent requirements on prescribing, dispensing, and storage.
• United Kingdom: Classified as a Class B controlled substance.
• Australia: Classified as a Schedule 8 controlled drug.
• New Zealand: Classified as a Class B2 controlled drug, with prescribing restricted to specialists like pediatricians or psychiatrists.

Global Regulatory Approval History

• United States (FDA): First approved in 2007 for the treatment of ADHD. The indication was expanded in January 2015 to include moderate-to-severe BED in adults. The first generic versions of lisdexamfetamine were approved by the FDA in August 2023.
• Canada (Health Canada): Approved in February 2009.
• European Union: Approved for medical use in 2012.

Brand Names, Generic Availability, and Commercial Landscape

• Brand Names: The most common brand name is Vyvanse in the United States and Canada. In the European Union, it is marketed as Elvanse. Other brand names include Arynta.
• Generic Availability: Following the expiration of market exclusivity, multiple pharmaceutical companies began manufacturing generic lisdexamfetamine dimesylate capsules and chewable tablets in the U.S. starting in late 2023. These generics are identifiable by different imprints on the capsules.
• Commercial Context: Lisdexamfetamine is a widely prescribed medication. In 2022, it was the 69th most commonly prescribed drug in the United States, with over 9 million prescriptions filled.

Conclusion

Lisdexamfetamine represents a significant advancement in stimulant pharmacotherapy. Its innovative prodrug design provides a unique pharmacokinetic profile characterized by a gradual onset and a prolonged, consistent duration of action, which offers clinical advantages for managing ADHD and BED with a single daily dose. The efficacy in both disorders underscores the critical role of dopaminergic and noradrenergic pathways in regulating executive function and impulse control. However, its clinical utility is balanced by a significant safety and regulatory profile. As a Schedule II controlled substance with a black box warning for abuse and dependence, its prescription demands a high degree of clinical vigilance, including careful patient assessment and ongoing monitoring for cardiovascular and psychiatric adverse effects. The recent introduction of generic formulations is poised to increase access to this important therapeutic agent, further solidifying its role in the management of ADHD and BED while reinforcing the need for responsible prescribing practices.

Works cited

1. Lisdexamfetamine (dimesylate) Synthetic Routes - MedKoo Biosciences, accessed August 2, 2025, https://www.medkoo.com/drug_syntheses/245
2. Lisdexamfetamine: MedlinePlus Drug Information, accessed August 2, 2025, https://medlineplus.gov/druginfo/meds/a607047.html
3. Lisdexamfetamine - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Lisdexamfetamine
4. Lisdexamfetamine | C15H25N3O | CID 11597698 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lisdexamfetamine
5. Vyvanse Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed August 2, 2025, https://www.drugs.com/vyvanse.html
6. CAS 608137-32-2: Lisdexamfetamine | CymitQuimica, accessed August 2, 2025, https://cymitquimica.com/cas/608137-32-2/
7. Adderall vs. Vyvanse: What's the Difference? - American Addiction Centers, accessed August 2, 2025, https://americanaddictioncenters.org/stimulants/amphetamine/adderall/vs-vyvanse
8. VYVANSE ® (lisdexamfetamine dimesylate ... - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf
9. FDA approves multiple generics of ADHD and BED treatment, accessed August 2, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment
10. Lisdexamfetamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01255
11. Is Vyvanse a controlled substance / narcotic drug? - Drugs.com, accessed August 2, 2025, https://www.drugs.com/medical-answers/vyvanse-controlled-substance-narcotic-drug-3542679/
12. lisdexamfetamine | 608137-32-2 - ChemicalBook, accessed August 2, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB12498819.htm
13. Lisdexamfetamine (mesylate) [A neat solid] - LGC Standards, accessed August 2, 2025, https://www.lgcstandards.com/PR/en/Lisdexamfetamine-mesylate-A-neat-solid-/p/CAY-18050
14. Lisdexamfetamine | 608137-32-2 - SynZeal, accessed August 2, 2025, https://www.synzeal.com/br/lisdexamfetamine-
15. medlineplus.gov, accessed August 2, 2025, https://medlineplus.gov/druginfo/meds/a607047.html#:~:text=Lisdexamfetamine%20is%20in%20a%20class,natural%20substances%20in%20the%20brain.
16. Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2873712/
17. Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder, accessed August 2, 2025, https://www.ahdbonline.com/issues/2016/march-2016-vol-9-seventh-annual-payers-guide/2149-vyvanse-lisdexamfetamine-dimesylate-first-fda-approved-drug-for-the-treatment-of-adults-with-binge-eating-disorder-may
18. Adderall vs. Ritalin vs. Vyvanse: Comparing ADHD Medications » AuDHD Psychiatry, accessed August 2, 2025, https://www.audhdpsychiatry.co.uk/adderall-ritalin-vyvanse-comparison/
19. Schedules of Controlled Substances: Placement of Lisdexamfetamine into Schedule II - Federal Register, accessed August 2, 2025, https://www.federalregister.gov/documents/2007/02/22/E7-2993/schedules-of-controlled-substances-placement-of-lisdexamfetamine-into-schedule-ii
20. Summary Basis of Decision - Vyvanse TM - Health Canada, accessed August 2, 2025, https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?linkID=SBD00311&lang=en
21. FDA Approves First Drug for Binge-Eating Disorder | Psychiatric News - Psychiatry Online, accessed August 2, 2025, https://psychiatryonline.org/doi/10.1176/appi.pn.2015.3a14
22. Lisdexamfetamine Completed Phase 2 Trials for Major Depressive Disorder (MDD) Treatment | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01255/clinical_trials?conditions=DBCOND0030181&phase=2&purpose=treatment&status=completed
23. What Is Vyvanse (lisdexamfetamine) Used For? - Healthline, accessed August 2, 2025, https://www.healthline.com/health/drugs/vyvanse-uses
24. Lisdexamfetamine - brand name list from Drugs.com, accessed August 2, 2025, https://www.drugs.com/ingredient/lisdexamfetamine.html
25. Chronic Fatigue Syndrome (CFS) Completed Phase 4 Trials for Lisdexamfetamine (DB01255) | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/indications/DBCOND0066154/clinical_trials/DB01255?phase=4&status=completed
26. Dependence, Cocaine Completed Phase 1 / 2 Trials for Lisdexamfetamine (DB01255), accessed August 2, 2025, https://go.drugbank.com/indications/DBCOND0045954/clinical_trials/DB01255?phase=1%2C2&status=completed
27. Lisdexamfetamine Completed Phase 1 / 2 Trials for Substance-Related Disorders / Attention Deficit Hyperactivity Disorder (ADHD) / Amphetamine-Related Disorders Treatment - DrugBank, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01255/clinical_trials?conditions=DBCOND0006032%2CDBCOND0041782%2CDBCOND0032942&phase=1%2C2&purpose=treatment&status=completed
28. Vyvanse, Arynta (lisdexamfetamine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 2, 2025, https://reference.medscape.com/drug/vyvanse-arynta-lisdexamfetamine-342993
29. Vyvanse (lisdexamfetamine): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed August 2, 2025, https://www.goodrx.com/vyvanse/what-is
30. Lisdexamfetamine dimesylate (oral route) - Side effects & dosage - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/lisdexamfetamine-dimesylate-oral-route/description/drg-20070888
31. Spotlight on lisdexamfetamine - Medsafe, accessed August 2, 2025, https://www.medsafe.govt.nz/profs/PUArticles/March2024/Spotlight-on-lisdexamfetamine.html
32. Vyvanse Interactions Checker - Drugs.com, accessed August 2, 2025, https://www.drugs.com/drug-interactions/lisdexamfetamine,vyvanse.html
33. Lisdexamfetamine Interactions - Drugs.com, accessed August 2, 2025, https://www.drugs.com/drug-interactions/lisdexamfetamine.html
34. Vyvanse interactions: Alcohol, medications, and other factors, accessed August 2, 2025, https://www.medicalnewstoday.com/articles/drugs-vyvanse-interactions
35. Ritalin vs. Adderall: 8 Differences Between These ADHD Stimulant Meds - GoodRx, accessed August 2, 2025, https://www.goodrx.com/conditions/adhd/ritalin-vs-adderall
36. What Attention Deficit Hyperactivity Disorder (ADHD) medication, Ritalin (methylphenidate) or lisdexamphetamine (Vyvanse), has the least side effects? - Dr.Oracle, accessed August 2, 2025, https://www.droracle.ai/articles/94323/adhd-medication-least-side-effects-ritalin-vs-lisdexamphetamine-
37. Schedules of Controlled Substances: Placement of Lisdexamfetamine Into Schedule II - Federal Register, accessed August 2, 2025, https://www.federalregister.gov/documents/2007/05/03/E7-8421/schedules-of-controlled-substances-placement-of-lisdexamfetamine-into-schedule-ii
38. Vyvanse® Generics Now FDA Approved - Partners For Kids, accessed August 2, 2025, https://partnersforkids.org/news-updates/vyvanse-generics-now-fda-approved/